Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Novacyt

Market Cap 30.58M 35.4M 28.18M 26.38M 49.43M 3.37B 50.2M 333M 130M 1.64B 133M 130M 5.67B P/E Ratio 2026 *
-
P/E Ratio 2027 * -
Enterprise Value 32.53M 37.67M 29.98M 28.06M 52.59M 3.58B 53.41M 354M 138M 1.74B 141M 138M 6.03B EV / Sales 2026 *
1.07x
EV / Sales 2027 * 1.02x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 day+2.93%
1 week-8.26%
Current month-28.47%
1 month-47.05%
3 months+8.90%
6 months-2.09%
Current year+7.93%
1 week 0.39
Extreme 0.39
0.46
1 month 0.39
Extreme 0.39
0.7
Current year 0.29
Extreme 0.29
1.04
1 year 0.29
Extreme 0.29
1.04
3 years 0.29
Extreme 0.29
1.59
5 years 0.29
Extreme 0.29
5.89
10 years 0.06
Extreme 0.0612
13.96
Manager TitleAgeSince
Chief Executive Officer 53 2024-04-30
Director of Finance/CFO 44 2019-12-31
Chief Operating Officer - 2021-10-31
Director TitleAgeSince
Director/Board Member 75 2006-07-02
Director/Board Member 60 2017-06-26
Director/Board Member 44 2024-01-01
Date Insider Type Main position Quantity % Market Cap.
Mar. 29Buy

Chief Executive Officer

15,149 0.0214%
Mar. 29Buy

Chairman

1,802 0.0026%
Mar. 29Buy

Chief Executive Officer

1,792 0.0025%
Change 5-day change 1-year change 3-year change Capi.($)
+2.93%-8.26%-26.86%-12.45% 35.4M
+4.16%+2.73%+248.11% - 549M
-2.44%-3.74%-41.18%-38.98% 536M
+2.73%-1.39%-26.92%+24.48% 144M
0.00%-10.90%+61.08%+98.18% 131M
Average +1.48%-0.17%+42.85%+17.81% 279.19M
Weighted average by Cap. +1.06%+3.04%+84.08%-5.86%

Financials

2026 *2027 *
Net sales 30.52M 35.34M 28.13M 26.33M 49.34M 3.36B 50.11M 332M 129M 1.64B 133M 130M 5.66B 34.86M 40.36M 32.12M 30.07M 56.35M 3.84B 57.23M 379M 148M 1.87B 151M 148M 6.47B
Net income - -
Net Debt 1.96M 2.26M 1.8M 1.69M 3.16M 215M 3.21M 21.28M 8.3M 105M 8.5M 8.32M 363M 4.84M 5.61M 4.46M 4.18M 7.83M 533M 7.95M 52.69M 20.54M 259M 21.04M 20.59M 898M
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216
Date Price Change Volume
26-06-12 0.4220 +2.93% 264,754
26-06-11 0.4100 -2.38% 359,298
26-06-10 0.4200 -2.44% 529,702
26-06-09 0.4305 -6.21% 250,148
26-06-08 0.4590 -0.22% 351,201

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALNOV Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!